The KRAS gene encodes a small G protein on the EGFR pathway.
•
Cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer (mCRC), in combination with chemotherapy, and as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.
Cetuximab, a monoclonal antibody against EGFR, has been used in compassionate use for treatment of Ménétrier's disease.